In afternoon trade the S&P/ASX 200 (Index: ^AXJO) (ASX: XJO) is on course to have a positive start to the week. At the time of writing the benchmark index is up 0.1% to 5,686 points.
Four shares which have started the week with strong gains are listed below. Here's why they are higher:
The Bubs Australia Ltd (ASX: BUB) share price is up 4% to 54 cents despite there being no news out of the infant formula company. While I saw value in its shares when they drifted down to 45 cents, I feel now they have rallied to 54 cents they ought to be classed as a hold.
The GetSwift Ltd (ASX: GSW) share price appears to have shaken off the profit takers and has climbed 8% to $2.15. The logistic platform provider's shares have more than doubled in value in less than a month thanks to a game-changing contract with US-giant NA Williams. Despite the strong gain, I still believe GetSwift is a great buy and hold investment option.
The Mayne Pharma Group Ltd (ASX: MYX) share price has rebounded from last week's drop with a 3% rise to 67.5 cents. The pharmaceutical company's shares fell 11% last week as concerns over competitive pressures in the U.S. generic drugs market weighed heavily on its shares.
The Mesoblast limited (ASX: MSB) share price has climbed almost 4% to $1.39 after the innovative cell-based medicines developer advised that its will present corporate updates at two healthcare conferences in New York this week. The focus will be on the Phase 3 clinical trials of its lead product candidates in acute graft versus host disease, chronic low back pain due to disc degeneration, and chronic heart failure.
